Zobrazeno 1 - 10
of 10 430
pro vyhledávání: '"Reporting System"'
Autor:
Permatasari, Paulina, Budiarso, Adi, Dartanto, Teguh, Samosir, Agunan Paulus, Saputro, Bramantya, Ekayana, Dewa, Agustono, Efid Dwi, Alim, Tri Emil, Hartono, Leni, Wahyuputri, Firli Wulansari, Wardhana, Irwanda Wisnu
Publikováno v:
Transforming Government: People, Process and Policy, 2024, Vol. 18, Issue 4, pp. 512-528.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/TG-07-2023-0098
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Tolvaptan-associated hepatic disorder is a rare, but lethal adverse event; however, the precise risk and time of onset remain unclear. This study aimed to characterize the severity, time‑to‑onset, and outcomes of hepatic disorder based o
Externí odkaz:
https://doaj.org/article/9e08396737fb4812ad71000cb8037e4b
Autor:
E. V. Shubnikova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 3, Pp 309-330 (2024)
INTRODUCTION. Postmarketing surveillance is the main mechanism to monitor and evaluate the safety of drugs approved for widespread clinical use. This mechanism provides up-to-date information on adverse drug reactions and facilitates the implementati
Externí odkaz:
https://doaj.org/article/4627d7be30994585930da3fb93840522
Publikováno v:
Journal of Medicine and Life Science, Vol 21, Iss 3, Pp 83-91 (2024)
Adverse drug reactions (ADRs) are closely associated with increased morbidity and mortality rates, prolonged hospitalization durations, and higher healthcare costs. This study aimed to estimate the incidence, clinical features, and reporting status o
Externí odkaz:
https://doaj.org/article/1c2564fdf62e4915aa65780ccfb9a7d4
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug interactions associate
Externí odkaz:
https://doaj.org/article/5fe85e835f69445692ad453ca97b9064
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Publikováno v:
Vascular Health and Risk Management, Vol Volume 20, Pp 415-420 (2024)
Mariko Kozaru, Hiroko Kambara, Akari Higuchi, Tatsuki Kagatsume, Keiko Hosohata Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-1094, JapanCorrespondence: Ke
Externí odkaz:
https://doaj.org/article/b61c939650e645acb2715f0d048cdeb7
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Trastuzumab emtansine (T-DM1) is widely utilized as a second-line and subsequent treatment for metastatic HER2+ breast cancer and has shown promise in early breast cancer treatment, particularly in adjuvant settings for residual disease afte
Externí odkaz:
https://doaj.org/article/cf8ea2b8612645708a91c061907a0d54
Publikováno v:
Risk Management and Healthcare Policy, Vol Volume 17, Pp 1639-1646 (2024)
Nam-Yi Kim,1 Hyonshik Ryu,2,* Sungjung Kwak3,* 1Department of Nursing, Konyang University, Daejeon, Republic of Korea; 2Department of Emergency Medicine, Konyang University Hospital, Daejeon, Republic of Korea; 3Department of Nursing, Howon U
Externí odkaz:
https://doaj.org/article/ab9b6e99383e41168b34afde83fe1ec4
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adve
Externí odkaz:
https://doaj.org/article/5ae4c212c0f64944b6212f9b26ad5e1c